Peripheral Vascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the peripheral vascular devices market size is expected to increase from USD 13.92 billion in 2025 to USD 14.5 billion in 2026 and reach USD 17.80 billion by 2031, growing at a CAGR of 4.18% over 2026-2031.

This report is Segmented by Device Type (Angioplasty Balloons, Angioplasty Stents, Atherectomy Devices, Thrombectomy Devices, Embolic Protection Devices, IVC Filters, Peripheral Guidewires, Others), Clinical Application (PAD, CLI, DVT, Other), End User (Hospitals, Ascs, Obls, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are in Value (USD).

Global Peripheral Vascular Devices Market Trends and Insights

Rapid Rise in Peripheral Artery & Venous Disease Prevalence

Medicare claims showed a 19% jump in lower-extremity revascularizations between 2019 and 2024, even while average length of stay fell 23%, underscoring the push for faster, device-intensive therapy. Deep-vein thrombosis incidence across OECD members increased 8% annually over 2020-2025, fueled by post-COVID sequelae and obesity. The American Heart Association positioned DVT as the third largest acute cardiovascular syndrome in its 2025 update, elevating it from a niche condition to a mainstream interventional focus.

Shift Toward Minimally-Invasive, Catheter-Based Revascularization

Open bypass volumes in the United States dropped 31% between 2015 and 2024, while percutaneous interventions rose 47%. Drug-eluting stents now deliver 78% 5-year patency in femoropopliteal disease, neutralizing the historic durability edge of surgery. Japan's 2024 reimbursement decision on atherectomy prompted a 40% spike in procedure counts the next quarter.

Device Reimbursement Cuts in the US & Select EU Markets

The 2026 CMS bundled-payment ceiling of USD 18,500 per 90-day PAD episode forces hospitals to secure 15-25% device discounts. Germany trimmed lower-extremity DRG weights 8% in 2025; United Kingdom guidance now limits first-line DCB use to in-stent restenosis, curbing premium-technology uptake.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Adoption of Drug-Coated Balloon Technology
2. Growth of Office-Based Labs in OECD Nations
3. Safety Concerns Over Paclitaxel-Eluting Peripherals

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Atherectomy revenue is expected to post an 8.22% CAGR between 2026-2031, the highest among device classes. The peripheral vascular devices market share for angioplasty balloons was 35.18% in 2025, but aggressive price competition from Asian generics cut average selling prices 12% compared with 2022. The peripheral vascular devices market size for atherectomy systems is projected to reach a significant revenue by 2031, alongside the calcium-heavy lesion mix and supportive coding in Japan and Australia. Directional atherectomy plus DCB achieved 81% 18-month patency in calcified vessels per the DEFINITIVE LE data set. Hospitals, however, cap usage to imaging-confirmed severe calcification because a single catheter still costs USD 2,500-3,500.

Second-tier products illustrate polarization. Thrombectomy adoption surged after FDA clearance of aspiration systems for iliofemoral DVT in 2024. Self-expanding stents edge toward commoditization, with vendors pivoting to fracture-resistant alloys and thinner strut profiles. IVC filters have declined after updated ACCP guidelines against prophylactic use, whereas guidewires and sheaths anchor low-margin but indispensable recurring revenue streams.

Complete Report Scope:

• By Device Type
  • Angioplasty Balloons
  • Angioplasty Stents
  • Atherectomy Devices
  • Thrombectomy Devices
  • Embolic Protection Devices
  • Inferior Vena Cava (IVC) Filters
  • Peripheral Guidewires
  • Others
• By Clinical Application
  • Peripheral Arterial Disease (PAD)
  • Critical Limb Ischaemia (CLI)
  • Deep Vein Thrombosis (DVT)
  • Other Clinical Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Office-Based Labs (OBLs)
  • Specialty Vascular & Cardiology Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America provided 42.25% of 2025 revenue. The United States braces for tempered growth as payment caps and site-of-care migration drive negotiations that pull average device spend per case down to USD 1,800 in ASCs versus USD 2,400 in hospitals. Canada invested in cath-lab capacity, yet provincial wait times of 12 weeks restrain volume. Mexico's private-hospital tier moves ahead with lithotripsy and limus balloons, contrasting with resource-limited public institutions.

Asia-Pacific is on track for a 7.68% CAGR. China's peripheral vascular devices market benefits from domestic champions capturing significant market share through aggressive pricing. India's Pradhan Mantri Swasthya Suraksha Yojana accelerates cath-lab installations beyond tier-1 metros, narrowing care disparities. Japan's aging diabetogenic population fuels PAD prevalence, though device spend per case averages USD 1,600 amid shorter hospital stays. Australia's 2025 OBL item numbers position it as a proving ground for next-wave sirolimus balloons.

Europe contributes sizeable absolute dollars, yet heterogenous reimbursement rules split adoption curves. Germany reimburses DCBs as first-line therapy, while the United Kingdom caps DCBs for restenosis. France green-lit orbital atherectomy in 2024. Eastern Europe, reliant on earlier-generation balloons, receives EU structural funds earmarked for cath-lab upgrades that will underpin gradual technology catch-up.

1. Abbott Laboratories
2. AngioDynamics
3. Asahi Intecc Co., Ltd.
4. Beckton Dickinson
5. BIOTRONIK
6. Boston Scientific
7. Cardinal Health
8. Cardiovascular Systems
9. Cook Group
10. iVascular S.L.U.
11. Medtronic
12. MicroPort
13. Nipro
14. Penumbra
15. Philips Healthcare (Spectranetics)
16. Shockwave Medical Inc.
17. Teleflex
18. Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support